FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McGuire Jonathan Will 		2. Issuer Name and Ticker or Trading Symbol

SECOND SIGHT MEDICAL PRODUCTS INC [ EYES ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

12744 SAN FERNANDO ROAD, SUITE 400 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/19/2017
(Street)

SYLMAR, CA 91342
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/18/2017   5/18/2017   M    11875   (1) A $1.16   71673   D    
Common Stock   5/19/2017     D    4562   D $1.1499   67111   (2) D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrant to Purchase Common Stock   $1.47                    3/14/2017   3/14/2022   Common Stock   6794     6794   D    
Non-Qualified Stock Option (right to buy)   $1.97                    1/3/2018   (3) 1/3/2027   Common Stock   571330     571330   D    
Non-Qualified Stock Option (right to buy)   $4.1                    1/21/2017   (3) 1/21/2026   Common Stock   21290     21290   D    
Non-Qualified Stock Option (right to buy)   $12.43                    8/17/2016   (3) 8/17/2025   Common Stock   420000     420000   D    
Restricted Stock Unit (RSU)     (4) 5/19/2017   5/19/2017   M         11875    8/17/2016   (3) 8/17/2019   Common Stock   190000     (5) 106875   D    

Explanation of Responses:
(1)  11,875 shares of common stock acquired upon quarterly vesting of Restricted Stock Units (RSUs).
(2)  4,562 shares were sold to satisfy the tax withholding requirements on vesting of RSUs.
(3)  Options and RSUs vest over a 4 year term, with 25% vesting on the Date Exercisable as set forth in this Form 4 and thereafter vesting in 12 equal quarterly installments of 6.25%.
(4)  Each restricted stock unit represents a contingent right to receive one share of common stock of the Company.
(5)  Not Applicable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
McGuire Jonathan Will
12744 SAN FERNANDO ROAD
SUITE 400
SYLMAR, CA 91342 		X
Chief Executive Officer

Signatures
/s/ Jonathan Will McGuire 5/22/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Second Sight Medical Pro... Charts.
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Second Sight Medical Pro... Charts.